We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current NWPHF market cap is 214.14M. The company's latest EPS is EUR -0.9091 and P/E is -13.20.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 7.04M | 5.26M | 5.76M | 6.09M | 9.06M |
| Operating Income | -20.9M | -18.07M | -12.36M | -13.3M | -11.63M |
| Net Income | -20.21M | -21M | -14.9M | -17.49M | -16.22M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 60.29M | 51.2M | 50.49M | 37.2M | 25.87M |
| Total Liabilities | 23.49M | 33.95M | 47.38M | 51.23M | 55.77M |
| Total Equity | 36.8M | 17.25M | 3.11M | -14.03M | -29.91M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -22.21M | -15.59M | -11.45M | -11.09M | -10.14M |
| Investing | -932k | -616k | 8.42M | -317k | 3.25M |
| Financing | 17.57M | 7.37M | 14.83M | -186k | -192k |
| Market Cap | 214.14M |
| Price to Earnings Ratio | -13.20 |
| Price to Sales Ratio | 23.65 |
| Price to Cash Ratio | 33.78 |
| Price to Book Ratio | -7.16 |
| Dividend Yield | - |
| Shares Outstanding | 17.85M |
| Average Volume (1 week) | 100 |
| Average Volume (1 Month) | 668 |
| 52 Week Change | 92.93% |
| 52 Week High | 12.00 |
| 52 Week Low | 5.22 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Newron Pharmaceuticals SPA (GM) |
| Address |
via antonio meucci 3, bresso milan, lombardy 20091 |
| Website | https://www.newron.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
